



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PRODUCT INFORMATION




SB-649868

Item No. 29477

CAS Registry No.: 380899-24-1
Formal Name: N-[[[(2S)-1-[[[5-(4-fluorophenyl)-2-methyl-4-thiazolyl]carbonyl]-2-piperidinyl]methyl]-4-benzofurancarboxamide

Synonym: GSK 649868
MF: C₂₆H₂₄FN₃O₃S
FW: 477.6
Purity: ≥98%
UV/Vis.: λ_{max}: 210, 268 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

SB-649868 is supplied as a crystalline solid. A stock solution may be made by dissolving the SB-649868 in the solvent of choice, which should be purged with an inert gas. SB-649868 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of SB-649868 in these solvents is approximately 0.3, 10, and 15 mg/ml, respectively.

SB-649868 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, SB-649868 should first be dissolved in DMF and then diluted with the aqueous buffer of choice. SB-649868 has a solubility of approximately 0.04 mg/ml in a 1:20 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

SB-649868 is a dual antagonist of orexin 1 receptor (OX1R) and OX2R (K_is = 0.31 and 0.39 nM, respectively).¹ *In vivo*, SB-649868 (3 and 10 mg/kg) decreases wakefulness and latency to fall asleep in rats.² It also reduces binge eating of highly palatable food in a female rat model of stress-induced binge eating.

References

1. Winrow, C.J. and Renger, J.J. Discovery and development of orexin receptor antagonists as therapeutics for insomnia. *Br. J. Pharmacol.* **171**(2), 283-293 (2014).
2. Piccoli, L., Micioni Di Bonaventura, M.V., Cifani, C., *et al.* Role of orexin-1 receptor mechanisms on compulsive food consumption in a model of binge eating in female rats. *Neuropsychopharmacology* **37**(9), 1999-2011 (2012).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 05/18/2020

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM